Neoplasm News and Research

RSS

Neoplasm is an abnormal mass of tissue as a result of neoplasia.

What is the tolerability profile and rate of recurrent CDI after administrating microbiome therapeutic SER-109 post-antibiotic treatment?

Researchers investigated the tolerability and safety of a microbiome therapy called SER-109 to treat recurrent infections of Clostridioides difficile in adults.

15 Feb 2023

New research examines how COVID-19 affects immune-compromised people

Researchers evaluate outcomes in immunocompromised patients hospitalized with COVID-19.

5 Feb 2023

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 Jan 2023

Study suggests a strategy for preventing the progression of chronic leukemia to aggressive disease

A study from Washington University School of Medicine in St. Louis suggests a strategy for preventing a chronic, slow-growing type of blood cancer from progressing to an aggressive form of leukemia.

29 Dec 2022

Study identifies a subset of melanoma patients with very low risk of death

Although melanoma is the most serious type of skin cancer, most patients have high chances of surviving the disease.

7 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

Amplification of venous thromboembolism risk by COVID-19 among malignancy patients

In a new study, researchers reported the mechanisms involved in COVID-19 coagulopathy and the significance of SARS-CoV-2 infections for cancer patients concerning outcomes, thromboembolic complication risks, and consequences of management strategies.

14 Oct 2022

OpenSAFELY-TPP data is broadly representative of the English population

Researchers evaluated the representativeness of the OpenSAFELY-TPP data to the general English population

28 Jun 2022

Development of QCC-targeting therapeutic agents may lead to new cancer treatments

Announcing a new review article publication for Acta Materia Medica journal. Quiescent cancer cells (QCCs) reversibly reside in G0 phase, thus allowing them to survive chemotherapy and radiotherapy, which generally target proliferating cells.

10 Feb 2022

Phenome study reveals alternate associations with SARS-CoV-2 risk loci

Researchers from the Duke Molecular Physiology Institute have been investigating genetic associations with more severe disease and examining the associations that certain genetic features have with other diseases.

13 Dec 2021

Researchers use game theory to understand how cells compete in tumors

Game theory applied to cell encounters inside a tumor provides a sociological perspective on the possible behaviors of cells in a collectivity, and offers a more comprehensive understanding of the complex rules that govern a neoplasm.

18 Oct 2021

Automated system based on AI helps rule out cancer in women with dense breasts

An automated system that uses artificial intelligence (AI) can quickly and accurately sift through breast MRIs in women with dense breasts to eliminate those without cancer, freeing up radiologists to focus on more complex cases, according to a study published in Radiology.

5 Oct 2021

Neoplasm News and Research

Further Reading

What is the tolerability profile and rate of recurrent CDI after administrating microbiome therapeutic SER-109 post-antibiotic treatment?

New research examines how COVID-19 affects immune-compromised people

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Study suggests a strategy for preventing the progression of chronic leukemia to aggressive disease

Study identifies a subset of melanoma patients with very low risk of death

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

Amplification of venous thromboembolism risk by COVID-19 among malignancy patients

OpenSAFELY-TPP data is broadly representative of the English population

Development of QCC-targeting therapeutic agents may lead to new cancer treatments

Phenome study reveals alternate associations with SARS-CoV-2 risk loci

Researchers use game theory to understand how cells compete in tumors

Automated system based on AI helps rule out cancer in women with dense breasts

Novel combination therapy approach to keep leukemia at bay

Prediction models may reduce false-positive MRI screenings in women with dense breasts

Novel method provides faster and more precise diagnostics in histopathology

Gift boosts efforts to understand and combat rare cancers

New grant to Harvard Medical School is boosting efforts to understand and combat rare cancers

New cancer immunotherapy uses engineered T cells to target a common genetic alteration

Scientists characterize genomic profile of 84 pediatric therapy-related myeloid neoplasms

Novel endoscopic technique improves detection of upper GI tract tumors

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News